By This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Top News
- Anesthetic and Analgesic Drug Products Advisory Committee Roster
- Drug Safety and Risk Management Advisory Committee Roster
- FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma
- Pain and Arthritis Products Containing Hidden Ingredients
- Painflex Forte may be harmful due to hidden drug ingredients
- Max Chemical Inc. – 682037 – 06/20/2024
- Her Neighbor of 15 Years Turned Out to Be Family—thanks to DNA
- 6 Things to Do in Ennis, Texas—From Bluebonnet Trails to a Railroad Museum
- ATM Glitch is Causing Chase to Sue Over 1,000 People—Were You Part of It?
- She Rescued a Dog on a Mountain—And He Rescued Her Family, Too
- April 21 to April 27 Horoscope Forecast: Your Zodiac Sign’s Week
- More Money Found: 11 Refunds and Credits You Can Get on Common Expenses
- NB Industry accelerates global shift despite US overtures to China
- Delta Electronics sees India gains amid global tariff war, eyes local expansion
- CloudMile highlights mixed progress in Southeast Asia’s AI development
- Router maker TP-Link faces US criminal antitrust investigation
- Intel to continue boosting in-house chip production, braces for tariff impacts
- Intel Foundry sales rise, losses narrow as company unveils major cost-cutting plan
